Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia bpth_aml_fpd20161102
Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference BPTH_Rodman_20160906
BIO-PATH HOLDINGS TO ANNOUNCE SECOND QUARTER 2016 FINANCIAL RESULTS ON AUGUST 10, 2016 BPTH_EarnsAnnounce_20160803
Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference BPTH_Cantor_2016
Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering BPTH_2016_Registered_Direct_Offering
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01 BP1001 Review Article See Also: BP1001 animal studies BP1001 leukemia cell line studies
Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer BPTH_TJU_PR_20160628
Bio -Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 BPTH_ASCO2016_Final
